| 项目编号 |
PRJCA013528 |
| 项目标题 |
Amplification of chromosome 11q13 associated with primary resistance to PD-1 blockade in unresectable hepatocellular carcinoma |
| 涉及领域 |
Medical |
| 数据类型 |
Targeted Locus (Loci)
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
A total of 62 HCC patients who underwent next-generation sequencing were retrospectively included in our department for this study. PD-1 inhibitors intervention (PD-1Ab) group and nonPD-1Ab group included 20 and 13 patients, respectively. Chromosome 11q13 amplification (Amp11q13) was the most common copy number variation in our cohort. Fifteen patients harbored Amp11q13 in our dataset. Des-γ-carboxy- prothrombin (DCP), albumin (ALB), tumor number and portal vein tumor thrombus (PVTT) were different between the Amp11q13 group and the nonAmp11q13 group. In the PD-1Ab group, the proportion of primary resistance in patients with Amp11q13 was significantly higher than that in patients with nonAmp11q13. In the PD-1Ab group, the median progression-free survival (PFS) was 1.5 months in Amp11q13 patients vs 16.2 months in non-Amp11q13 patients. HCC patients with Amp11q13 are less likely to benefit from PD-1 blockade therapies. These findings may help guide the use of immunotherapy for HCC in routine clinical practice. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2022-11-28 |
| 出版信息 |
| PubMed ID |
文章标题 |
杂志名称 |
Doi |
发表年份 |
| 37056769
|
Chromosome 11q13 amplification correlates with poor response and prognosis to PD-1 blockade in unresectable hepatocellular carcinoma
|
Frontiers in Immunology
|
10.3389/fimmu.2023.1116057
|
2023
|
|
|
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| No funding support
|
|
|
|
|
|
| 提交者 |
Dongyu
Liu (dongyu.liu@3dmedcare.com)
|
| 提交单位 |
3D Medicines Inc. |
| 提交日期 |
2022-11-28 |
